SEGMENT INFORMATION (Details) - Segments Information - USD ($)	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Oct. 31, 2019
Net loss:
Net Loss	$ (2,616,575)	$ (4,966,609)
Total operating costs and expenses	2,629,869	4,983,728
Less non-cash share-based compensation	(1,021,334)	(2,750,164)
Operating costs and expenses excluding non-cash share-based compensation	1,608,535	2,233,564
Total assets:
Total Assets	6,163,951		$ 6,293,693
Operating Segments [Member] | Cancer Diagnostics [Member]
Net loss:
Net Loss	(1,790,646)	(1,804,354)
Operating costs and expenses excluding non-cash share-based compensation	1,163,924	759,534
Total assets:
Total Assets	4,411,569		2,921,784
Operating Segments [Member] | Cancer Therapeutics [Member]
Net loss:
Net Loss	(825,929)	(2,487,285)
Operating costs and expenses excluding non-cash share-based compensation	444,611	800,791
Total assets:
Total Assets	1,604,596		2,872,341
Operating Segments [Member] | Patent Licensing [Member]
Net loss:
Net Loss		(674,970)
Operating costs and expenses excluding non-cash share-based compensation		$ 673,239
Total assets:
Total Assets	$ 147,786		$ 499,568